Medicare drug spending is rising faster than anticipated, largely due to the surging utilization of GLP-1 medications. This trend is occurring alongside the financial impacts of the Democrats' redesign of Part D drug coverage. The increased cost burden highlights the growing influence of peptide-based weight loss drugs on federal healthcare budgets.